capecitabine has been researched along with Neuroendocrine Tumors in 73 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (6.85) | 29.6817 |
| 2010's | 39 (53.42) | 24.3611 |
| 2020's | 29 (39.73) | 2.80 |
| Authors | Studies |
|---|---|
| Halfdanarson, TR; Kommalapati, A; Sonbol, MB; Starr, JS; Tella, SH | 1 |
| Dos Santos, J; Mesquita, A; Silva, DJ; Vaz, AP | 1 |
| Al-Toubah, T; Morse, B; Strosberg, J | 2 |
| Dong, J; Gao, H; Li, H; Liu, L; Wang, W; Xu, H; Ye, L; Yu, X; Zhang, W | 1 |
| Dogan, I; Karabulut, S; Sakar, B; Tastekin, D | 1 |
| Arrivi, G; Bagnardi, V; Fazio, N; Frassoni, S; Gervaso, L; Laffi, A; Rubino, M; Spada, F | 1 |
| Chun, JW; Douangprachanh, S; Han, N; Han, SS; Jang, HY; Joo, HJ; Kim, TH; Koh, YH; Lee, WJ; Park, HM; Park, SJ; Woo, SM | 1 |
| Badesha, J; Boutin, M; Farnell, D; Gill, S; Loree, JM; Mathews, A; Paul, A; Safro, M; Schaeffer, D; Stuart, HC | 1 |
| Chatterjee, D; Itani, M; Navale, P; Trikalinos, NA | 1 |
| Ağdaş, G; Ak, N; Akay, B; Akyıldız, A; Alan, Ö; Arak, H; Aydınalp, Y; Azizy, A; Bayram, D; Bilgin, B; Büyükbayram, ME; Büyükşimşek, M; Çağlayan, M; Canaslan, K; Çetin, B; Çoban, E; Demirci, A; Derin, S; Dursun, B; Ercelep, Ö; Erdal, GŞ; Eryılmaz, MK; Evrensel, T; Göksu, SS; Gümüş, M; Güven, DC; Güzel, HG; Hendem, E; Kahvecioğlu, FA; Kalkan, Z; Karabulut, S; Karataş, F; Kefeli, U; Kılıçkap, S; Köş, FT; Ön, S; Ordu, Ç; Oruç, Z; Özçelik, M; Özdemir, N; Paksoy, N; Paydaş, S; Sağlam, S; Sakin, A; Salim, DK; Şanlı, UA; Selvi, O; Şendur, MAN; Sever, N; Seyyar, M; Şimşek, M; Taştekin, D; Tatlı, AM; Topçu, A; Turna, ZH; Uğraklı, M; Ünal, Ç; Ünek, İT; Ürün, Y; Uygun, K; Yalçın, Ş; Yaşar, S; Yazıcı, O; Yücel, KB | 1 |
| Backen, A; Kordatou, Z; Lamarca, A; Mansoor, W; McCallum, L; Nasralla, M; Nonaka, D; Papaxoinis, G | 1 |
| Barriuso, J; Hubner, RA; Lamarca, A; Manoharan, P; Mansoor, W; McNamara, MG; Valle, JW | 1 |
| Alexandraki, KI; Angelousi, A; Chatzellis, E; Daskalakis, K; Gross, D; Grozinsky-Glasberg, S; Kaltsas, G; Kos-Kudła, B; Koumarianou, A; Maimon, O; Meirovitz, A; Tsoli, M; Wachula, E | 1 |
| Abdel-Misih, S; Cloyd, JM; Dillhoff, ME; Dua, M; Konda, B; Norton, JA; Pawlik, TM; Poultsides, G; Schmidt, CR; Shah, MH; Squires, MH; Visser, BC; Worth, PJ | 1 |
| Bergquist, JR; Chang, EM; Dua, MM; Li, AY; Scott, GD; Visser, BC | 1 |
| Chen, J; Jin, KZ; Li, YL; Liang, Y; Peng, Y; Tan, HY; Wang, W; Yu, XJ; Zhang, Y; Zhou, ZW | 1 |
| Antonuzzo, L; Barberis, M; Campana, D; Faviana, P; Fazio, N; Fumagalli, C; Gelsomino, F; Maisonneuve, P; Marconcini, R; Messerini, L; Puliafito, I; Rossi, G; Spada, F | 1 |
| Halfdanarson, TR; Leventakos, K; Molina, JR; Uprety, D | 1 |
| Basu, S; Bhandare, MS; Bhargava, P; Chaudhari, V; Ostwal, V; Parghane, RV; Ramaswamy, A; Shah, M; Shrikhande, SV; Srinivas, S | 1 |
| Bongiovanni, A; Calpona, S; Cocchi, C; De Vita, A; Di Menna, G; Fausti, V; Foca, F; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Riva, N; Spadazzi, C | 1 |
| Al-Toubah, T; Morse, B; Pelle, E; Strosberg, J | 1 |
| Buckner Petty, SA; Halfdanarson, TR; Hobday, TJ; Kendi, AT; Liu, AJ; McGarrah, PW; Sonbol, MB; Starr, J; Ueberroth, BE | 1 |
| Bodei, L; Bongiovanni, A; Caroli, P; Cittanti, C; Di Iorio, V; Diano, D; Grana, CM; Grassi, I; Ibrahim, T; Monti, M; Nicolini, S; Paganelli, G; Pieri, F; Sansovini, M; Sarnelli, A; Severi, S | 1 |
| Claringbold, PG; Grover, P; Kesavan, M; Lam, WS; Turner, JH | 1 |
| Colao, A; Faggiano, A; Ferraù, F; Lania, A; Modica, R; Rubino, M | 1 |
| Al-Toubah, T; Haider, M; Pelle, E; Strosberg, JR; Valone, T | 1 |
| Dong, J; Gao, H; Li, H; Liu, L; Ni, Q; Wang, W; Xu, H; Ye, L; Zhang, W | 1 |
| Bal, C; Ballal, S; Damle, NA; Sahoo, RK; Yadav, MP | 1 |
| Ahmad, R; Cao, Y; Du, F; Jiang, J; Ma, X; Ren, D; Shen, G; Wang, Z; Zhang, H; Zhang, S; Zhao, F; Zhao, J; Zheng, F | 1 |
| Dureja, S; Gupta, SK; Kumar, S; Kumari, J; Malasani, V; Pant, V; Sen, I; Thakral, P; Un, P | 1 |
| Cengel, KA; Damjanov, N; Metz, DC; Soulen, MC; Teitelbaum, UR; van Houten, D | 1 |
| Fu, W; Li, W; Lu, L; Lu, Y; Lv, W; Wang, J; Zhao, Z | 1 |
| Amoroso, V; Berruti, A; Bertani, E; Cella, CA; Fazio, N; Laffi, A; Maisonneuve, P; Pellicori, S; Pozzari, M; Spada, F | 1 |
| Brizzi, MP; Di Maio, M; La Salvia, A; Muratori, L; Scagliotti, GV; Trevisi, E | 1 |
| Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T | 1 |
| Ahmadzadehfar, H; Ahrens, H; Brossart, P; Essler, M; Feldmann, G; Fottner, C; Gaertner, FC; Miederer, M; Schreckenberger, M; Weber, MM; Yordanova, A | 1 |
| Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T | 1 |
| Joseph, R; Mathews, S; McRee, AJ; Zeidner, JF | 1 |
| Alexandraki, KI; Angelousi, A; Chatzellis, E; Daskalakis, K; Gross, D; Grozinsky-Glasberg, S; Kaltsas, G; Kos-Kudła, B; Koumarianou, A; Maimon, O; Meirovitz, A; Tsoli, M; Wachuła, E | 1 |
| Costa, FP; Gumz, B; Pasche, B | 1 |
| Ng, J; Ove, R; Russo, S; Saif, MW | 1 |
| Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW | 1 |
| Armstrong, G; Caplin, ME; Corrie, PG; Cunningham, D; Hardy, R; Lao-Sirieix, SH; Luong, TV; Meyer, T; Navalkissoor, S; Qian, W; Reed, N; Shaw, A; Talbot, DC; Valle, JW | 1 |
| Saif, MW; Tejani, MA | 1 |
| Amoroso, V; Berruti, A; Biasco, G; Birocco, N; Bodei, L; Brizzi, MP; D'Avolio, A; Dogliotti, L; Fazio, N; Ferrero, A; Nobili, E; Papotti, M; Priola, AM; Torta, M; Tozzi, L; Volante, M | 1 |
| Claringbold, PG; Kesavan, M; Turner, JH | 1 |
| Abbasi, S; Albaba, H; Kashashna, A | 1 |
| Baudin, E; Bengrine-Lefevre, L; Cadiot, G; Dominguez-Tinajero, S; Dromain, C; Ducreux, M; Farace, F; Kurtz, JE; Mitry, E; Rougier, P; Ruszniewski, P; Walter, T | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Claringbold, PG; Turner, JH | 1 |
| Backen, A; Barriuso, J; Elliott, E; Hubner, R; Lamarca, A; McNamara, MG; Valle, JW | 1 |
| Balise, RR; Bergsland, EK; Fehrenbacher, L; Fisher, GA; Hwang, J; Ko, AH; Korn, WM; Kunz, PL; Pan, M; Tempero, MA; Venook, AP | 1 |
| Beyer, DT; Boudreaux, JP; Chauhan, A; Ramirez, RA; Wang, YZ; Woltering, EA | 1 |
| Bedossa, P; Couvelard, A; Cros, J; Gille, N; Hammel, P; Hentic, O; Lévy, P; Maire, F; Paradis, V; Rebours, V; Ruszniewski, P; Theou-Anton, N; Vernerey, D; Zappa, M | 1 |
| Kesavan, M; Turner, JH | 1 |
| Black, M; Brelsford, M; Cives, M; Ghayouri, M; Meeker, A; Morse, B; Rizzo, A; Strosberg, J | 1 |
| Aller, J; Alonso, V; Alonso-Gordoa, T; Barriuso, J; Capdevila, J; Carmona-Bayonas, A; Crespo, G; Custodio, A; Gajate, P; Grande, E; Jiménez-Fonseca, P; López, C; Matos, I; Navarro, M; Nieto, B; Sevilla, I | 1 |
| An, C; He, X; Hua, X; Kong, X; Liu, X; Matkar, S; Wang, L; Xie, G | 1 |
| Abou-Alfa, GK; Blumgart, LH; Capanu, M; D'Angelica, M; Dematteo, RP; Duffy, A; Fong, Y; Huitzil, D; Jarnagin, W; O'Reilly, EM | 1 |
| Hicks, RJ; Hubble, D; Johnson, V; Kong, G; Michael, M; Ramdave, S | 1 |
| Eriksson, B | 1 |
| Brayshaw, PA; Claringbold, PG; Price, RA; Turner, JH | 1 |
| Davies, JM; Farrugia, D; Hayward, N; Kirichek, O; Medley, L; Morel, AN; Reed, N; Talbot, DC; Thakker, RV | 1 |
| Broadwater, G; Clough, RW; Czito, BG; Guy, CD; Papalezova, KT; Papavassiliou, P; Tyler, DS; White, RR; Willett, CG; Zagar, TM | 1 |
| Allen, JN; Arvold, ND; Blaszkowsky, LS; Clark, JW; Deshpande, V; Fernandez-del Castillo, C; Ferrone, CR; Hong, TS; Kwak, EL; Niemierko, A; Ryan, DP; Wadlow, RC; Warshaw, AL; Willett, CG; Zhu, AX | 1 |
| Claringbold, PG; Price, RA; Turner, JH | 1 |
| Centeno, B; Kvols, L; Morse, B; Saranga-Perry, V; Strosberg, J | 1 |
| Allendorf, J; Chabot, JA; Dinnen, RD; Fine, RL; Gulati, AP; Krantz, BA; Lee, JA; Mao, Y; Moss, RA; Mowatt, KB; Schreibman, S; Schrope, B; Sherman, WH; Stevens, PD; Tsushima, DA | 1 |
| Chin, S; Feld, R; Haider, M; Hu, H; Knox, J; Krzyzanowska, MK; Oza, AM; Siu, LL; Tsao, MS | 1 |
| Bajetta, E; Bajetta, R; Bichisao, E; Catena, L; De Dosso, S; Ferrari, L; Formisano, B; Martinetti, A; Platania, M; Procopio, G; Verzoni, E | 1 |
| Ammann, M; Duquesne, A; Fürstenberger, G; Schmid, P; Senn, HJ | 1 |
| de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M | 1 |
11 review(s) available for capecitabine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Management of well-differentiated neuroendocrine tumors.
Topics: Antineoplastic Agents; Capecitabine; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Somatostatin | 2021 |
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecitabine; Carcinoid Tumor; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Everolimus; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lymph Node Excision; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pneumonectomy; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Temozolomide; Watchful Waiting | 2020 |
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
Topics: Capecitabine; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Everolimus; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Pancreatic Neoplasms; Quality of Life; Radioisotopes; Somatostatin; Temozolomide; Treatment Outcome | 2021 |
Novel fluoropyrimidine-based chemotherapy for advanced well-differentiated neuroendocrine tumors: a clinical update.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm Staging; Neuroendocrine Tumors; Oxonic Acid; Pyrimidines; Tegafur; Treatment Outcome | 2018 |
Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Observational Studies as Topic; Survival Analysis; Temozolomide | 2018 |
Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cytoreduction Surgical Procedures; Humans; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Sunitinib; Temozolomide; Vascular Endothelial Growth Factor A | 2018 |
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Proliferation; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Intestinal Neoplasms; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Prognosis; Stomach Neoplasms; Streptozocin; Temozolomide | 2012 |
Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Dacarbazine; Everolimus; Humans; Neuroendocrine Tumors; Octreotide; Temozolomide; Thalidomide | 2015 |
Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free Survival; Fluorouracil; Gastrointestinal Neoplasms; Humans; Interferons; Neuroendocrine Tumors; Radiopharmaceuticals; Somatostatin; Streptozocin; Temozolomide | 2016 |
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Octreotide; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Temozolomide | 2016 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome | 2010 |
12 trial(s) available for capecitabine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Topics: Capecitabine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prospective Studies | 2021 |
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Temozolomide; Treatment Outcome | 2021 |
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Quality of Life; Streptozocin; Surveys and Questionnaires; Treatment Outcome | 2014 |
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Topics: Administration, Metronomic; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Treatment Outcome | 2014 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2014 |
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neuroendocrine Tumors; Treatment Outcome | 2014 |
Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Temozolomide; Tomography Scanners, X-Ray Computed; Treatment Outcome | 2016 |
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Fluorouracil; Humans; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2016 |
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Deoxycytidine; Disease Progression; Endocrine Gland Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pilot Projects; Radiometry; Salvage Therapy; Treatment Outcome | 2011 |
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors | 2011 |
Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Temozolomide; Treatment Outcome | 2012 |
Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumours.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Capecitabine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Lactones; Middle Aged; Neuroendocrine Tumors; Sulfones | 2006 |
50 other study(ies) available for capecitabine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Rectal mixed adenoneuroendocrine carcinoma: Case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fatal Outcome; Humans; Male; Mixed Tumor, Malignant; Neuroendocrine Tumors; Oxaliplatin; Radiotherapy; Rectal Neoplasms; Rectum | 2021 |
Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neuroendocrine Tumors; Retrospective Studies; Temozolomide | 2022 |
The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neuroendocrine Tumors; Prospective Studies; Retrospective Studies; Temozolomide | 2022 |
Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Retrospective Studies; Temozolomide; Treatment Outcome | 2022 |
Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single-center retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neuroendocrine Tumors; Quality of Life; Retrospective Studies; Treatment Outcome | 2022 |
Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Treatment Outcome | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
Topics: Adult; Aged; Capecitabine; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Mutation; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Tuberous Sclerosis | 2023 |
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Temozolomide; Treatment Outcome; Turkey | 2023 |
Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Female; Humans; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Outcome Assessment, Health Care; Prognosis; Retrospective Studies; Temozolomide | 2020 |
Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Temozolomide; Treatment Outcome | 2020 |
Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration.
Topics: Capecitabine; Duration of Therapy; Fluorouracil; Humans; Neuroendocrine Tumors; Temozolomide | 2020 |
Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administ
Topics: Capecitabine; Dacarbazine; Duration of Therapy; Humans; Neuroendocrine Tumors; Temozolomide | 2020 |
Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Progression-Free Survival; Registries; Retrospective Studies; Temozolomide; Time Factors; United States | 2020 |
Nearing the Summit: Associating Liver Partitioning and Portal Ligation for Staged Hepatectomy (ALPPS) in Progressive Carcinoid Disease.
Topics: Antineoplastic Agents; Capecitabine; Disease Progression; Female; Hepatectomy; Humans; Liver; Liver Neoplasms; Liver Regeneration; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2020 |
A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Capecitabine; Drug Therapy, Combination; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Neuroendocrine Tumors; Outcome Assessment, Health Care; Prognosis; Retrospective Studies; Temozolomide; Young Adult | 2021 |
Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Italy; Neuroendocrine Tumors; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies; Temozolomide; Treatment Outcome | 2021 |
Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Drug Combinations; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Outcome Assessment, Health Care; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Temozolomide | 2021 |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Outcome Assessment, Health Care; Temozolomide | 2021 |
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Leucovorin; Neuroendocrine Tumors; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Treatment Outcome | 2021 |
Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.
Topics: Capecitabine; Humans; Middle Aged; Neuroendocrine Tumors; Prospective Studies; Retrospective Studies; Treatment Outcome | 2021 |
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Treatment Outcome | 2021 |
Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Sunitinib; Temozolomide | 2022 |
Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study.
Topics: Adolescent; Adult; Aged; Capecitabine; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Quality of Life; Safety; Survival Analysis; Young Adult | 2017 |
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabine; Case-Control Studies; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Intestinal Neoplasms; Liver; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Spleen; Stomach Neoplasms; Temozolomide; Tissue Distribution | 2018 |
Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Embolization, Therapeutic; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thrombocytopenia; Yttrium Radioisotopes | 2018 |
Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours - single-centre experience of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Neuroendocrine Tumors; Temozolomide; Treatment Outcome | 2019 |
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Digestive System Neoplasms; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Propensity Score; Temozolomide | 2019 |
Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Temozolomide | 2019 |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Temozolomide | 2020 |
Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chromosome Inversion; Chromosomes, Human, Pair 16; Female; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Neuroendocrine Tumors; Palliative Care; Prognosis; Temozolomide | 2019 |
Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Prognosis; Progression-Free Survival; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2019 |
Radiotherapy in the management of pancreatic neuroendocrine tumors (PNET): experience at three institutions.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant | 2013 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Remission Induction; Retrospective Studies; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2013 |
Pancreatic neuroendocrine tumors: does chemotherapy work?
Topics: Algorithms; Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Cell Differentiation; Dacarbazine; Deoxycytidine; Developing Countries; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Jordan; Male; Middle Aged; Neuroendocrine Tumors; Remission Induction; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2014 |
The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Temozolomide | 2016 |
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2016 |
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co-Repressor Proteins; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Middle Aged; Molecular Chaperones; Neuroendocrine Tumors; Nuclear Proteins; Pancreatic Neoplasms; Telomere; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; X-linked Nuclear Protein | 2016 |
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Proportional Hazards Models; Spain; Survival Analysis; Temozolomide; Treatment Outcome | 2017 |
BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells.
Topics: Antineoplastic Agents; Benzodiazepines; Capecitabine; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Dacarbazine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Neuroendocrine Tumors; Nuclear Proteins; Octreotide; Protein Stability; RNA, Messenger; S-Phase Kinase-Associated Proteins; Temozolomide; Transcription Factors; Transcriptional Activation; Ubiquitin-Protein Ligases; Ubiquitination; Up-Regulation | 2017 |
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Cholecystectomy, Laparoscopic; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Incidental Findings; Male; Middle Aged; Neoplasm, Residual; Neuroendocrine Tumors; Radiotherapy, Adjuvant; Retrospective Studies; Sarcoma; Survival Analysis | 2008 |
177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hematologic Tests; Humans; Kidney; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Prodrugs; Radiation-Sensitizing Agents; Receptors, Peptide; Retrospective Studies; Survival Analysis; Time Factors; Young Adult | 2010 |
Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrimidines; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure | 2012 |
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Sex Factors; Tumor Burden | 2012 |
Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thymus Neoplasms; Treatment Outcome | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2013 |
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chromogranin A; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Analysis | 2007 |
Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromogranin A; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2008 |
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Creatinine; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, Intravenous; Leukocyte Count; Male; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Platelet Count; Radioisotopes; Receptors, Somatostatin | 2008 |